eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study

Sorafenib may reduce endothelial nitric oxide synthase (eNOS) activity by inhibiting vascular endothelial growth factor receptors (VEGF-R), leading to a decrease in nitric oxide production. In the Italian multicenter ePHAS (eNOS polymorphisms in HCC and sorafenib) study, we analyzed the role of eNOS...

Descripción completa

Detalles Bibliográficos
Autores principales: Gardini, Andrea Casadei, Marisi, Giorgia, Faloppi, Luca, Scarpi, Emanuela, Foschi, Francesco Giuseppe, Iavarone, Massimo, Lauletta, Gianfranco, Corbelli, Jody, Valgiusti, Martina, Facchetti, Floriana, Corte, Cristina della, Neri, Luca Maria, Tamberi, Stefano, Cascinu, Stefano, Scartozzi, Mario, Amadori, Dino, Nanni, Oriana, Tenti, Elena, Ulivi, Paola, Frassineti, Giovanni Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053704/
https://www.ncbi.nlm.nih.gov/pubmed/27058899
http://dx.doi.org/10.18632/oncotarget.8569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053704/
https://www.ncbi.nlm.nih.gov/pubmed/27058899
http://dx.doi.org/10.18632/oncotarget.8569

Ejemplares similares